Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high‐risk salivary gland carcinomas

Abstract

Until prospective evidence is available, such as from Radiation Therapy Oncology Group 1008, the standard use of CRT for advanced salivary malignancies cannot be recommended. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.

High metastatic node number, not extranodal extension, as a node‐related prognosticator in surgically treated patients with nodal metastatic salivary gland carcinoma

“…Despite the small subject numbers in each treatment arm, our data suggest that the presence of ENE in patients with SGC may not justify aggressive treatment intensification as HNSCC. In the literature, several retrospective series have demonstrated that adding concomitant chemotherapy to adjuvant irradiation is not associated with survival advantages . Among older patients, the use of chemoradiation is even associated with increased mortality .…”

Submandibular gland cancer: Specific features and treatment considerations

“…Chemotherapy is mainly restricted to locally recurrent or distant metastatic disease, although CRT may not improve survival . Still, contradictory results have been reported .…”

Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database

“…Apart from small, single‐institution studies, there is a lack of evidence in the literature for the use of adjuvant chemotherapy in salivary gland tumors beyond its use for inoperable or metastatic disease. Recent studies have suggested increased toxicity and no survival benefit associated with the addition of chemotherapy to the standard adjuvant therapy of postoperative radiotherapy of salivary gland malignancies . A Radiation Therapy Oncology Group clinical trial aiming to address the efficacy of adjuvant chemoradiotherapy is ongoing and has an estimated completion date of October 2023 (NCT01220583).…”